Apollomics

Apollomics

Apollomics

Apollomics is an innovative biopharmaceutical company committed to the discovery and development of oncology combination therapies.
Founded
2016
Raised
$100M
Follow us
Alexa global traffic share
Twitter followers
Latest funding
$100,000,000
Venture capital (Series B) - 2019
OrbiMed Cmb International Pan-Lin Asset Management +4
Team Size
1–10
Employees
$100,000,000 Venture capital (Series B)
PE HUB , ChinaMoneyNetwork

Apollomics racks up $100 mln Series B

FinSMEs

Apollomics Raises $100M in Series B Financing